Remdesivir
- Generic Name
- Remdesivir
- Brand Names
- Veklury
- Drug Type
- Small Molecule
- Chemical Formula
- C27H35N6O8P
- CAS Number
- 1809249-37-3
- Unique Ingredient Identifier
- 3QKI37EEHE
- Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp)...
- Indication
Remdesivir is indicated for the treatment of adult and pediatric patients 28 days of age and older and weighing at least 3 kg for coronavirus disease 2019 (COVID-19) infection requiring hospitalization. It is also indicated for the treatment of non-hospitalized patients with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, ...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Immune Modulators for Treating COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Daniel Benjamin
- Target Recruit Count
- 1971
- Registration Number
- NCT04593940
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇺🇸University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2023-06-05
- Target Recruit Count
- 527
- Registration Number
- NCT04583969
- Locations
- 🇺🇸
Stony Brook Medicine - Stony Brook University Hospital, Stony Brook, New York, United States
🇺🇸University of Utah - Infectious Diseases, Salt Lake City, Utah, United States
🇺🇸Hoag Hospital Newport Beach, Newport Beach, California, United States
ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2023-05-16
- Target Recruit Count
- 214
- Registration Number
- NCT04583956
- Locations
- 🇺🇸
Kern Medical Center, Bakersfield, California, United States
🇺🇸Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States
🇺🇸Boston Medical Center - Center for Infectious Diseases - Shapiro Center, Boston, Massachusetts, United States
PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2023-06-09
- Target Recruit Count
- 54
- Registration Number
- NCT04582266
- Locations
- 🇺🇸
Bronx-Lebanon Hospital Center (Site #: 5114), Bronx, New York, United States
🇺🇸David Geffen School of Medicine at UCLA (Site #: 5112), Los Angeles, California, United States
🇺🇸Pediatric Perinatal HIV Clinical Trials Unit (Site #: 5127), Miami, Florida, United States
An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Professor Dr. Bernd Mühlbauer
- Target Recruit Count
- 400
- Registration Number
- NCT04575064
- Locations
- 🇩🇪
Universitätsklinikum Gießen, Gießen, Germany
🇩🇪Medizinische Hochschule Hannover (MHH), Hannover, Germany
🇩🇪Gesundheit Nord gGmbH, Bremen, Germany
Remdesivir in COVID-19 Lahore General Hospital
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Lahore General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04560231
- Locations
- 🇵🇰
Muhammad Irfan Malik, Lahore, Punjab, Pakistan
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
- Conditions
- Interventions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 593
- Registration Number
- NCT04546581
- Locations
- 🇺🇸
CHRISTUS Spohn Shoreline Hospital, Corpus Christi, Texas, United States
🇬🇧Royal Free Hospital, London, United Kingdom
🇬🇷3rd Dept of Medicine, Medical School, NKUA, Athens, Greece
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- UNICEF
- Target Recruit Count
- 600
- Registration Number
- NCT04492501
- Locations
- 🇵🇰
Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-03-14
- Target Recruit Count
- 969
- Registration Number
- NCT04492475
- Locations
- 🇺🇸
Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States
🇺🇸University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 1500
- Registration Number
- NCT04488081
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.